In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

Deals in Depth: May 2024

Six $1bn+ alliances were penned in May. In the top alliance by deal value, AC Immune SA granted Takeda an option to license exclusive global rights to active immunotherapies targeting toxic forms of amyloid beta, including ACI-24.060 for the treatment of Alzheimer’s disease. AC Immune will receive $100m up front and is eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1bn, plus sales royalties.

Deals Financing

Biopharma Market’s Green Shoots Are Evident But Full Recovery Must Wait Awhile

Biopharma markets may follow the downward trajectory of tech during tough times, but they also chase it back up the value curve. Recovery is just a matter of time, says Seventure’s Isabelle de Crémoux in this commentary on investment trends, the financial markets and the VC environment.

Market Intelligence Financing

Gene Therapy’s Next Target: Our Microbes

CRISPR pioneer Jennifer Doudna recently co-launched an initiative focused on microbial gene editing, but French biotech Eligo has been diligently working on this for 10 years. 

Innovation Gene Therapy

Deals Shaping The Industry, May 2024

An interactive look at pharma, medtech and diagnostics deals made during May 2024. Data courtesy of Biomedtracker.

Deals Financing

‘AI-volution’ In Life Sciences? Unveiling Trends in Worldwide Patent Filings

Computing, including AI, applied to life sciences is undeniably a rapidly growing area, driven by significant investment, recent technological advancements and heightened public interest. A look at published patents from 2014 to 2023 reveals trends in patent filings across various life sciences sectors and highlights geographical hotspots.

Patents Companies

Jazz’s CNS Pipeline Demonstrates Transformation

With a first-in-class cannabis-derived treatment for epilepsy, a market-leading treatment for sleep disorders and now a foray into movement disorders, Jazz’s CNS pipeline is strong.

Market Intelligence Neurology

Japan’s Biotech Ecosystem Could Be Headed For An Upswing

After decades of lackluster start-up innovation despite award-winning science, Japan’s government and big pharma players are taking steps to spur biotech growth. 

Market Intelligence Research & Development

Development Versus Dealmaking: How To Obtain A Blockbuster

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

Business Strategies Companies

The Truly Transformational Potential Of AI Relies On The Data

Executives from several AI-focused biotechs emphasize that generating a truly innovative medicine, as opposed to a me-too drug, depends not just on the quantity, but on the quality of data used by the algorithm.

Commercial Strategies Artificial Intelligence

Deals in Depth: April 2024

Seven $1bn+ alliances were penned in April. In the top alliance by deal value, Medincell entered a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will receive a $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones, plus mid-single to low-double-digit royalties on net sales.

Deals Financing

Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition?

With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.

Market Intelligence Commercial

Why Are Clinical Development Success Rates Falling?

A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?

Clinical Trials Market Intelligence

Deals Shaping The Industry, April 2024

An interactive look at pharma, medtech and diagnostics deals made during April 2024. Data courtesy of Biomedtracker.

Deals Financing

Dealmaking Quarterly Statistics, Q1 2024

During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device company M&A values reached $3.6bn, while in vitro diagnostics and research tools players’ M&A activity totaled $1bn.

Deals Market Intelligence

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Market Intelligence Sales & Earnings

Addex Gets Creative To Secure Funding And Its Future

Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.

Leadership Strategy
See All